Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	1.04B
Revenue (ttm)	170.24M
Net Income (ttm)	56.03M
Shares Out	15.94M
EPS (ttm)	3.43
PE Ratio	19.03
Forward PE	32.45
Dividend	1.89 (2.90%)
Ex-Dividend Date	Jun 4, 2025

Volume	26,074
Average Volume	18,908
Open	67.10
Previous Close	65.20
Day's Range	64.80 - 68.50
52-Week Range	41.60 - 74.40
Beta	1.28
RSI	58.15
Earnings Date	Oct 23, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR